Pgnx roc, just put the simpleton on ignore. He is an attention starved loser and you give him what he desperately wants by responding to him.you can reprt him as a spammer if that would make you feel better.
Not a bad analysis cadillac. SNTA has been hurt by inept management but fortunately they are looking for an new CEO. The I-SPY 2 represents a great opportunity so I wouldn't downplay it.
pgnxrox, you are looking at this wrong. Jmelink is here to provide us with some amusement as his expense as PGNX keeps rising after he keeps telling us why it won't. It is a gift we should enjoy. He will soon be telling us PGNX won't hold $5.50. After it does, it will be it won't hold $5.75. After t does, then it won't break $6…..
Don't get mad, just thank him for providing the laugh.
erick, you need to chill out and grab hold onto some reality. Fed chief Yellen made some ill-advised comments about specific market sectors, one of which was small biotechs. The market in these sectors immediately tanked so of course SNTA dropped. You start spouting off about how this confirms your "brilliant" stock picking prowess. Wow, talk about delusions of grandeur.
Some have talked about the recent FDA decision on Relistor label expansion as only being a possibility. That is wrong. The FDA gave approval for label expansion. Here is the SLXP press release from yesterday.
"On July 14, 2014, Salix Pharmaceuticals, Ltd. (the "Company") and Progenics Pharmaceuticals, Inc. ("Progenics") announced that the Food and Drug Administration had informed the Company that it had approved the supplemental New Drug Application for RELISTOR� (methylnaltrexone bromide) Subcutaneous Injection, 20 mg/ml, for the treatment of opioid-induced constipation in patients taking opioids for chronic non-cancer pain."
The fact that Yellen actually mention small biotechs just shows that she is very new to the job. If she feels the need to comment on stocks, them make one about the broader markets, or focus on financials and housing. It was a breath-taking lay amateurish move to mention small biotechs as a concern.
scotty, I see what you meant. I would still be a bit more cautious as to the $1.2 billion figure as I think 2017 is a bit optimistic. Even the good news on Relistor, we both know there are more positives to PGNX now. Good Luck
scotty, the $1.2 billion figure for oral Relistor sales from SLPX was for several years down the road, not in the next two years.
kdressen, first of all, there is no IF, what I stated is fact. Second, some shorts will lie and distort in order to sow fear and thereby hope to profit from it. That is truly loathsome and our board troll jmelink is of that ilk. Put the imbecile on ignore. Obviously not all shorts are like that and shorts do play an important role in the market.
It isn't surprising that some short term traders would book some profits and move on. When that comes on the day the market is tanking, some panic and sell or foolishly get caught on margin and are forced to sell. I look at such times as opportunities if the company's prospects are good. PGNX is now on much more solid footing, and most investors don't know that the $40 million milestone in coming to PGNX. In a few weeks, SLXP will have met with the FDA to finalize labeling issues and lay out the framework for post-approvla studies in a few weeks. The official announcement of FDA approval will be made, PGNX will get the milestone soon after. The next key for Relistor is how soon SLXP will meet with the FDA regarding ORAL Relistor, and how long its approval will take.
This is what SLXP will be doing in the net few weeks and then it will be official.
."In regard to the RELISTOR sNDA the Agency has directed Salix to work with and submit certain information to the Division of Gastroenterology and Inborn Errors Products (DGIEP). Salix intends to submit the requested information over the next several weeks. The requested information includes: proposed product labeling and a proposal(s) for one or more post-marketing observational cohort studies designed to assess the relative incidence of Major Adverse Cardiovascular Events (MACE) among chronic non-cancer pain patients initiating RELISTOR via subcutaneous injection for OIC versus a comparator cohort.
This request for a proposal for a post-marketing observational study is in accordance with recommendations of the June 11-12, 2014 meeting of the Anesthetic and Analgesic Drug Product Advisory Committee. Salix will work with the DGIEP in an effort to provide information to the Division that will enable the Division to approve RELISTOR for use by patients with chronic non-cancer pain and experiencing OIC."
Stop lying kdreesen. SLXP does NOT have to submit new data. The will be speaking with the FDA regarding post-apporval studies.
especially to the long-time nodes like Striperman and cafisherman. This was a long time coming and it is a shame that the FDA engaged in CYA two years ago to delay this day. Hopefully, the FDA will allow the oral formal to be approved with minimal hoops to jump through. If you listened to the CC, PGNXZ was asked about Oral formulation approval. They were cautiously optimistic as they didn't see anything obvious that would create a road-block for Oral Relistor, but that needs to be discussed with the FDA as soon as they can and that is on the agenda.
PGNX is also getting Azedra manufacturing back up to speed as the supplier lapsed before PGNX obtained it.